Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid effects.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Reversal of opioid overdose,Reversal of opioid-induced respiratory depression,Treatment of opioid-induced pruritus,Diagnosis of opioid dependence
Mild to moderate pain,Fever
0.4-2 mg IV/IM/SC, may repeat every 2-3 minutes; if no response after 10 mg, reconsider diagnosis.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
60-90 minutes in adults; shorter in neonates (3 hours); prolonged in hepatic impairment (up to 2-3 hours).
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via glucuronidation (UGT2B7) to naloxone-3-glucuronide; minor CYP450 involvement.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: ~70% as metabolites (naloxone-3-glucuronide, naloxone-3-sulfate) and <2% unchanged; biliary/fecal: ~25% primarily as conjugated metabolites.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~50-60% primarily to albumin; less bound than opioids.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
2.0-3.0 L/kg; high due to lipophilicity, distributing rapidly into tissues including brain.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: <2% (extensive first-pass metabolism); Intranasal: ~50%; IM/SC: near 100% with rapid absorption.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dose adjustment required; naloxone is not significantly renally eliminated.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dose adjustment required; naloxone undergoes extensive hepatic metabolism, but no guidelines exist for Child-Pugh adjustments.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
0.01-0.1 mg/kg IV/IM/SC, maximum 2 mg per dose; may repeat every 2-3 minutes as needed.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Use lower initial doses (0.4 mg) and titrate cautiously due to increased sensitivity and risk of withdrawal.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of precipitating severe opioid withdrawal in physically dependent patients; caution in neonates.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
May precipitate acute withdrawal; monitor for recurrent respiratory depression due to short half-life; use caution in opioid-dependent patients and neonates.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to naloxone; acute opioid withdrawal syndrome.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
None. Naloxone is not known to interact with food or beverages.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk; no adequate human studies in pregnant women. Naloxone crosses the placenta but has low bioavailability. Risk in first trimester is unknown; theoretical benefit in opioid reversal outweighs potential risk. Second and third trimesters: no known teratogenicity; may cause withdrawal in opioid-dependent fetus if maternal use reversed.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Naloxone is excreted into breast milk in small amounts. M/P ratio is unknown. Milk levels are low and unlikely to affect nursing infant. Oral bioavailability of naloxone is poor (<2%), so infant exposure via breast milk is minimal. Considered compatible with breastfeeding; use when clinically indicated.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No dose adjustment required during pregnancy. Pharmacokinetics of naloxone are not significantly altered by gestational changes. Use standard adult dosing for opioid reversal. Titrate to effect based on clinical response.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Naloxone has a short half-life (30-90 minutes) relative to many opioids, necessitating repeat doses or continuous infusion for long-acting opioid overdoses. In opioid-dependent patients, naloxone can precipitate acute withdrawal, which is distressing but not life-threatening. Use the smallest effective dose to reverse respiratory depression while minimizing withdrawal. Consider intranasal administration for ease of use in community settings; onset is slightly slower than IV but comparable efficacy. Monitor for recurrence of respiratory depression after initial reversal, especially with methadone, buprenorphine, or sustained-release formulations. In neonates, naloxone should be used cautiously due to risk of seizures; it is not recommended for routine resuscitation.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Naloxone is a life-saving emergency medication used to reverse opioid overdose; it has no effect if no opioids are present.,Call 911 immediately after administering naloxone; it is a temporary measure and medical help is essential.,After giving naloxone, stay with the person and monitor their breathing; rescue breaths may be needed.,Naloxone may cause withdrawal symptoms like agitation, nausea, sweating, and rapid heart rate; these are signs it is working.,Store naloxone at room temperature, protect from light, and check expiration dates regularly.,If the person does not respond within 2-3 minutes, a second dose may be given if available.,Even if the person wakes up, do not leave them alone; the effects of some opioids can last longer than naloxone, causing breathing to stop again.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE vs ACEPHEN, answered by our medical review team.
NALOXONE is a Opioid Antagonist that works by Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid effects.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE is: 0.4-2 mg IV/IM/SC, may repeat every 2-3 minutes; if no response after 10 mg, reconsider diagnosis.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE is classified as Category A/B. FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk; no adequate human studies in pregnant women. Naloxone crosses the placenta but has low bioavailabil. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.